- Clariant is expanding its Clear Lake, Texas site to add GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients.
- This is Clariant's first U.S. facility producing pharma-grade PEGs, targeting supply for North America with reach into Latin America.
- Manufacturing will follow excipient GMP standards and PEG products are registered in relevant pharmacopoeias to support regulated production and traceability.
- Expansion was announced March 19, 2026.
Project overview
On March 19, 2026 Clariant announced expansion of its Clear Lake, Texas site to add excipient GMP‑compliant manufacturing of pharmaceutical‑grade polyethylene glycol (PEG) excipients, its first U.S. facility for pharma‑grade PEGs, extending supply reach to North and Latin America.
Operational benefits
Regional production is intended to shorten lead times, improve supply‑chain resilience and responsiveness, reduce inventory carrying costs and provide greater predictability for pharmaceutical production planning and business continuity.
Quality and compliance
The Clear Lake upgrade was designed to meet rigorous quality, safety and regulatory expectations; excipient GMP compliance provides documentation, traceability and quality assurance, and the PEG products are registered in relevant pharmacopoeias with negligible toxicity profiles suitable for oral and topical applications.
